Neurohormonal activation and the management of heart failure

Keyphrases

• Heart Failure 100%
• Heart Failure Management 100%
• Neurohormonal Activation 100%
• Left Ventricular Function 60%
• Vasoconstrictor 40%
• Neurohormonal 40%
• Diuretic Therapy 40%
• Growth-promoting 40%
• Structural Change 20%
• Therapeutic Strategies 20%
• Left Ventricle 20%
• Adverse Effects 20%
• Drug Therapy 20%
• Progressive Disease 20%
• Disease Process 20%
• Developing World 20%
• Renin-angiotensin-aldosterone System 20%
• Sympathetic Nervous System 20%
• Vascular Bed 20%
• New Agents 20%
• Future Therapeutics 20%
• Study within a Trial 20%
• Inotropic 20%
• Structural Remodeling 20%
• Digitalis 20%
• Structural Damage 20%
• Functional Deficits 20%
• Fluid Accumulation 20%
• Inotropic Drugs 20%
• Functional Disturbances 20%
• Weber 20%
• Inhibitor Agent 20%
• Pharmacologic Management 20%
• Failure Data 20%
• Aldosterone Antagonists 20%
• Angiotensin-converting Enzyme Inhibitor (ACEi) 20%
• Favorable Effect 20%
• β-adrenergic Receptor Blocker 20%

Nursing and Health Professions

• Congestive Heart Failure 100%
• Carvedilol 66%
• Diuretic Therapy 33%
• Aldosterone 33%
• Diseases 33%
• Dipeptidyl Carboxypeptidase Inhibitor 16%
• Drug Therapy 16%
• Beta Adrenergic Receptor Blocking Agent 16%
• Angiotensin Receptor Antagonist 16%
• Pathophysiology 16%
• Angiotensin 16%
• Renin 16%
• Adverse Effect 16%

Biochemistry, Genetics and Molecular Biology

• Carvedilol 100%
• Inotropism 50%
• Enzyme Inhibitor 25%
• Angiotensin-Converting Enzyme 25%
• Renin Angiotensin Aldosterone System 25%
• Beta Blocker 25%
• Adrenergic Receptor 25%
• Angiotensin Receptor 25%
• Aldosterone 25%
• Drug Therapy 25%
• Adverse Effect 25%